BioSensics, has announced the launch of its Sensor-Integrated Digital Platform for measurement and remote monitoring of movement-based biomarkers in clinical trials. The platform combines clinical-grade wearable sensors with turnkey data transfer and storage solutions to enable objective and timely collection of sensor and ePRO data from trial participants. Clinically-validated algorithms enable assessment of a wide range of endpoints from the sensor data including physical activity, falls, gait, balance, frailty, and fatigue, as well as disease-specific motor symptoms such as tremor, chorea, and foot drop. Relevant therapeutic areas include stroke, Alzheimer’s disease, CNS and musculoskeletal disorders, orthopaedics, oncology, and many others.
The platform is driven by BioSensics’ wearable sensors which have been utilized in more than 50 clinical studies and over 200 scientific publications. The sensors gather data from participants during activities of daily living, while also alerting the clinical study staff in case of non-compliance in wearing the sensors. The platform includes a customizable ePRO interface via smartphone or tablet and allows for automatic data transfer to a HIPAA compliant cloud server.
“We are very excited about the positive impact of our wearable sensor technologies in clinical trials. For diseases that impact movement and mobility, assessing how new therapeutics improve patient motor function is critical for understanding treatment efficacy. Our clinical-grade sensors and algorithms, combined with our digital platform, provide a robust solution for measuring those critical movement-based biomarkers,” said Dr. Joseph T. Gwin, Vice President of Research and Development at BioSensics.
Learn more at www.biosensics.com/solutions/clinical-trials
